



Marina Klein
Canada

Dr. Marina Klein is a Professor of Medicine at McGill University, in Montreal, Quebec, Canada in the Division of Infectious Diseases/Chronic Viral Illnesses Service.

She graduated from McGill Medical School (1991) and received her training in Internal Medicine at the Royal Victoria Hospital in Montreal. She completed a research fellowship in Infectious Diseases at the University of Minnesota in 1998 and then returned to McGill University where she received a Master's degree in Epidemiology and Biostatistics (2003). Her clinical interests focus on the treatment of patients with HIV and chronic viral hepatitis. She is currently supported by a national clinician-scientist award from the Fonds de recherche santé – Québec. She focuses her research on clinical and epidemiologic aspects of HIV and Hepatitis C (HCV) co-infection and leads a Canadian Institutes of Health Research (CIHR) funded prospective cohort study of over 1400 HIV-HCV co-infected patients to study the interaction of these chronic viral infections in a translational research program. She has been a principal investigator in several clinical trials of HIV-HCV co-infection and has worked towards gaining access to liver transplantation for co-infected people in Canada. She is also involved in a number of observational epidemiologic research collaborations (NA-ACCORD and CANOC) focused on understanding long-term clinical and treatment outcomes in HIV and HIV-HCV co-infection, where she has assumed a leadership role in scientific steering committees. Additional research interests include pharmacoepidemiology of antiretroviral and immunologic outcomes, particularly in non-clade B virus HIV infection.

Dr. Klein has been active in the Canadian HIV Research community as a previous member of the Canadian Association of HIV Research governing council and as a member of the CIHR HIV/AIDS Research Advisory Committee. She is National Co-Director of the CIHR-CTN and Co-Leader of its Co-Infections and Concurrent Diseases Core. She is also a mentor in the Canadian Network for Hepatitis C and has worked with the Canadian Treatment Action Council.

Dr. Klein's work with the Canadian Co-Infection cohort has highlighted the extent to which vulnerabilities and co-morbidities are linked in negatively impacting health outcomes. This has led her to establish a research agenda focused on developing and implementing novel care models with the goal of improved diagnosis, management and increased access to treatment for vulnerable populations affected by HIV and HIV-HCV co-infection. Given the particular impact of co-infections on Aboriginal communities, she has been working to establish collaborations with indigenous researchers in Canada, Australia, and New Zealand. She is co-leader of the IAS Co-Infections initiative and has served as Co-chair of the IAS affiliated International HIV-Hepatitis Co-Infection Meeting 2015 and 2016.